Cargando…

Characteristics of Acquired Inhibitors to Factor VIII and Von Willebrand Factor Secondary to Systemic Lupus Erythematosus: Experiences From a Chinese Tertiary Medical Center

Because acquired hemophilia (AH) is a rare entity in systemic lupus erythematosus (SLE), we aimed to investigate the clinical features of SLE-related AH in Chinese patients. METHODS: This is a medical records review study carried out at a large tertiary care hospital in China from years 1986 to 2018...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xiao-Yu, Li, Meng-Tao, Zhang, Xuan, Zhao, Yan, Zeng, Xiao-Feng, Zhang, Feng-Chun, Hou, Yong, Zhu, Li-Xiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300847/
https://www.ncbi.nlm.nih.gov/pubmed/31815811
http://dx.doi.org/10.1097/RHU.0000000000001284
_version_ 1783726543138193408
author Cao, Xiao-Yu
Li, Meng-Tao
Zhang, Xuan
Zhao, Yan
Zeng, Xiao-Feng
Zhang, Feng-Chun
Hou, Yong
Zhu, Li-Xiu
author_facet Cao, Xiao-Yu
Li, Meng-Tao
Zhang, Xuan
Zhao, Yan
Zeng, Xiao-Feng
Zhang, Feng-Chun
Hou, Yong
Zhu, Li-Xiu
author_sort Cao, Xiao-Yu
collection PubMed
description Because acquired hemophilia (AH) is a rare entity in systemic lupus erythematosus (SLE), we aimed to investigate the clinical features of SLE-related AH in Chinese patients. METHODS: This is a medical records review study carried out at a large tertiary care hospital in China from years 1986 to 2018. We searched the case database in Peking Union Medical College Hospital using the International Classification of Diseases. The clinical data on SLE-related AH patients were collected. RESULTS: A total of 9282 SLE patients had been hospitalized. Six female SLE-related AH patients were identified. Four patients had acquired hemophilia A (AHA), and 2 patients had acquired von Willebrand syndrome. Their mean age was 33.67 ± 13.77 years. Five patients had active disease. The mean SLE disease activity index measured at the time of diagnosis of AH was 10.50 ± 5.28. The average level of activated partial thromboplastin time was 86.5 seconds. Coexistence of secondary antiphospholipid syndrome and AHA was found in one case, and pulmonary embolism was observed 3 years later. After immunosuppressive therapy and symptomatic treatment, an overall remission rate of 83.3% was achieved. CONCLUSIONS: The frequency of SLE-related AH was low. The development of AH in SLE patients frequently occurs with active disease. The AH could be the first clinical presentation of SLE. Secondary antiphospholipid syndrome and AHA could appear in the same SLE patient. Early and aggressive treatment contributes to a favorable prognosis.
format Online
Article
Text
id pubmed-8300847
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-83008472021-07-23 Characteristics of Acquired Inhibitors to Factor VIII and Von Willebrand Factor Secondary to Systemic Lupus Erythematosus: Experiences From a Chinese Tertiary Medical Center Cao, Xiao-Yu Li, Meng-Tao Zhang, Xuan Zhao, Yan Zeng, Xiao-Feng Zhang, Feng-Chun Hou, Yong Zhu, Li-Xiu J Clin Rheumatol Original Articles Because acquired hemophilia (AH) is a rare entity in systemic lupus erythematosus (SLE), we aimed to investigate the clinical features of SLE-related AH in Chinese patients. METHODS: This is a medical records review study carried out at a large tertiary care hospital in China from years 1986 to 2018. We searched the case database in Peking Union Medical College Hospital using the International Classification of Diseases. The clinical data on SLE-related AH patients were collected. RESULTS: A total of 9282 SLE patients had been hospitalized. Six female SLE-related AH patients were identified. Four patients had acquired hemophilia A (AHA), and 2 patients had acquired von Willebrand syndrome. Their mean age was 33.67 ± 13.77 years. Five patients had active disease. The mean SLE disease activity index measured at the time of diagnosis of AH was 10.50 ± 5.28. The average level of activated partial thromboplastin time was 86.5 seconds. Coexistence of secondary antiphospholipid syndrome and AHA was found in one case, and pulmonary embolism was observed 3 years later. After immunosuppressive therapy and symptomatic treatment, an overall remission rate of 83.3% was achieved. CONCLUSIONS: The frequency of SLE-related AH was low. The development of AH in SLE patients frequently occurs with active disease. The AH could be the first clinical presentation of SLE. Secondary antiphospholipid syndrome and AHA could appear in the same SLE patient. Early and aggressive treatment contributes to a favorable prognosis. Lippincott Williams & Wilkins 2021-08 2019-12-10 /pmc/articles/PMC8300847/ /pubmed/31815811 http://dx.doi.org/10.1097/RHU.0000000000001284 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Articles
Cao, Xiao-Yu
Li, Meng-Tao
Zhang, Xuan
Zhao, Yan
Zeng, Xiao-Feng
Zhang, Feng-Chun
Hou, Yong
Zhu, Li-Xiu
Characteristics of Acquired Inhibitors to Factor VIII and Von Willebrand Factor Secondary to Systemic Lupus Erythematosus: Experiences From a Chinese Tertiary Medical Center
title Characteristics of Acquired Inhibitors to Factor VIII and Von Willebrand Factor Secondary to Systemic Lupus Erythematosus: Experiences From a Chinese Tertiary Medical Center
title_full Characteristics of Acquired Inhibitors to Factor VIII and Von Willebrand Factor Secondary to Systemic Lupus Erythematosus: Experiences From a Chinese Tertiary Medical Center
title_fullStr Characteristics of Acquired Inhibitors to Factor VIII and Von Willebrand Factor Secondary to Systemic Lupus Erythematosus: Experiences From a Chinese Tertiary Medical Center
title_full_unstemmed Characteristics of Acquired Inhibitors to Factor VIII and Von Willebrand Factor Secondary to Systemic Lupus Erythematosus: Experiences From a Chinese Tertiary Medical Center
title_short Characteristics of Acquired Inhibitors to Factor VIII and Von Willebrand Factor Secondary to Systemic Lupus Erythematosus: Experiences From a Chinese Tertiary Medical Center
title_sort characteristics of acquired inhibitors to factor viii and von willebrand factor secondary to systemic lupus erythematosus: experiences from a chinese tertiary medical center
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300847/
https://www.ncbi.nlm.nih.gov/pubmed/31815811
http://dx.doi.org/10.1097/RHU.0000000000001284
work_keys_str_mv AT caoxiaoyu characteristicsofacquiredinhibitorstofactorviiiandvonwillebrandfactorsecondarytosystemiclupuserythematosusexperiencesfromachinesetertiarymedicalcenter
AT limengtao characteristicsofacquiredinhibitorstofactorviiiandvonwillebrandfactorsecondarytosystemiclupuserythematosusexperiencesfromachinesetertiarymedicalcenter
AT zhangxuan characteristicsofacquiredinhibitorstofactorviiiandvonwillebrandfactorsecondarytosystemiclupuserythematosusexperiencesfromachinesetertiarymedicalcenter
AT zhaoyan characteristicsofacquiredinhibitorstofactorviiiandvonwillebrandfactorsecondarytosystemiclupuserythematosusexperiencesfromachinesetertiarymedicalcenter
AT zengxiaofeng characteristicsofacquiredinhibitorstofactorviiiandvonwillebrandfactorsecondarytosystemiclupuserythematosusexperiencesfromachinesetertiarymedicalcenter
AT zhangfengchun characteristicsofacquiredinhibitorstofactorviiiandvonwillebrandfactorsecondarytosystemiclupuserythematosusexperiencesfromachinesetertiarymedicalcenter
AT houyong characteristicsofacquiredinhibitorstofactorviiiandvonwillebrandfactorsecondarytosystemiclupuserythematosusexperiencesfromachinesetertiarymedicalcenter
AT zhulixiu characteristicsofacquiredinhibitorstofactorviiiandvonwillebrandfactorsecondarytosystemiclupuserythematosusexperiencesfromachinesetertiarymedicalcenter